Agenda

Academic and Training Affairs in Collaboration with Department of Medical Oncology

Post Graduate Center Auditorium

King Faisal Specialist Hospital and Research Centre - Riyadh

Dear Colleagues,

On behalf of the organizing and scientific committee, it is our pleasure to invite you all to the Hybrid conference of the 3rd Controversies in GI/GU Oncology, hosted by the Cancer Center for Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

The success of our previous conferences on the Controversies in GI/GU Oncology has brought us once again to pursue another collective discussion in the treatment of these cancers that will hopefully shed light and advance our knowledge in the current standard treatment of Gastrointestinal and Genitourinary malignancies. It is with optimism that with very interesting scientific program that focuses on the different approaches in GI/GU cancer management, this debate format will give us another opportunity to know and learn novel treatment options and advance our knowledge in the field of Oncology.

Our local panel of experts from the different institutions and regions will be engaged in these interactive debates and educational presentation that covers the most controversial topics that may help medical practitioners towards optimal standard of care.

Your active participation in this oncology conference will certainly be very valuable and we wish everyone a productive educational experience in the debate sessions.

Finally, to our Sponsors who contributed to make this event possible, our utmost gratitude and appreciation for the enormous support.

Dr. Ahmed Badran Sobh Head, Organizing Committee

DAY 1: FRIDAY, 08 March 2024

OPENING SESSION

12:50 PM - 1:00 PM Welcome Remarks

SESSION 1: RCC

1:00 PM - 1:10 PM Role of radical nephrectomy in mRCC: Surgery vs Non-Surgery

1:10 PM - 1:20 PM Surgery vs. Non-Surgery

1:20 PM - 1:30 PM Discussion

1:30 PM - 1:40 PM Role of immunotherapy in metastatic non clear RCC

1:40 PM - 1:50 PM Yes or Against

1:50 PM - 2:00 PM Discussion

SESSION 2: UROTHELIAL

2:00 PM - 2:10 PM Role of adjuvant immunotherapy in invasive urothelial cancer

2:10 PM - 2:20 PM Adjuvant Immunotherapy vs No

2:20 PM - 2:30 PM Discussion

SATELLITE SYMPOSIUM | Sponsored by : IPSEN

2:30 PM - 3:00 PM Recent Advances in 1st Line mRCC

3:00 PM - 3:10 PM Break

Speaker: Shouki Bazarbashi, MD

Proponent favoring Surgery Sultan Alkhateeb, MD

Opponent against Surgery Abdulrahman Alloghbi, MD

Moderator Sohail Sarwar, MD

Proponent favoring IO Bassam Basulaiman, MD

Opponent against IO Safwan Bakhsh, MD

Moderator Ayman Elshentenawy, MD

Proponent favoring Adjuvant IO Mohammad Aseafan, MD

Opponent against IO Marwan Al-Hejeili, MD

Moderator Amer Zahralliyali, MD

Speaker Jens Bedke, MD

Moderator Shouki Bazarbashi, MD

DAY 1: FRIDAY, 08 March 2024

SESSION 3: PROSTATE

3:10 PM - 3:20 PM Triplet therapy vs doublet therapy in hormone sensitive prostate cancer

3:20 PM - 3:30 PM Triplet Therapy vs Doublet Therapy

3:30 PM - 3:40 PM Discussion

3:40 PM - 3:50 PM Hormone followed by hormone treatment vs hormone followed by chemo/others

3:50 PM - 4:00 PM HR>HR vs HR>Chemo

4:00 PM - 4:10 PM Discussion

4:10 PM - 4:20 PM PET PSMA guided in oligometastatic castrate sensitive prostate cancer

4:20 PM - 4:30 PM Yes or No

4:30 PM - 4:40 PM Discussion

SATELLITE SYMPOSIUM | Sponsored by : MERCK

4:40 PM - 5:10 PM Sequencing in Management of mUC

SESSION 4: TESTICULAR

5:10 PM - 5:20 PM Testicular cancer beyond first line: High dose chemotherapy vs conventional chemo

5:20 PM - 5:30 PM High dose chemotherapy vs conventional chemo

5:30 PM - 5:40 PM Discussion

End of Day 1 Sessions

Proponent favoring Triplet Roula Mufti, MD

Opponent favoring Doublet Abdullah Alsharm, MD

Moderator Essam Morshed, MD

Proponent favoring HR>HR Amin Eltigani, MD

Opponent favoring HR>Chemo Nedal Bukhari, MD

Moderator Ahmad Said Abdelmotal, MD

Proponent favoring PET PSMA Faisal Azam, MD

Opponent against PET PSMA Faisal Badainah, MD

Moderator Farah Habib, MD

Speaker Faizal Azam, MD

Moderator Abdullah Alsharm, MD

Proponent favoring High dose CTH Muhammad Rauf, MD

Opponent against Conventional CTH Sharif Kullab, MD

Moderator Sohal Athar, MD

DAY 2: SATURDAY, 09 March 2024

OPENING REMARKS

8:20AM - 8:30 AM Opening Remarks

SESSION 5: UPPER GI – GASTRIC/GE

8:30AM - 8:40 AM Treatment of localized GEJ tumors: Neo-adjuvant treatment

8:40AM - 8:50 AM CCRT vs CTH

8:50AM - 9:00 AM Discussion

9:00AM - 9:10 AM Treatment of oligometastatic GEJ adenocarcinoma metastatic directed therapy

9:10AM - 9:20 AM Yes vs. No

9:20AM - 9:30 AM Discussion

9:30AM - 9:40 AM Role of staging laparoscopy in gastric cancer

9:40AM - 9:50 AM Yes vs. No

9:50AM - 10:00 AM Discussion

10:00AM - 10:10 AM Break

10:10AM - 10:20 AM Neoadjuvant treatment for MSI-H gastric GEJ tumor

10:20AM - 10:30 AM FLOT vs ICI

10:30AM - 10:40 AM Discussion

10:40AM - 10:50 AM Role of ICI in metastatic gastric cancer: All or PDL expressors only

10:50AM - 11:00 AM Yes or No

11:00AM - 11:10 AM Discussion

SATELLITE SYMPOSIUM | Sponsored by : Bristol Myers Squibb (BMS)

11:10AM - 11:40 AM Role of IO in Treating UGI Cancers

Speaker: Ahmad Badran Sobh, MD

Proponent favoring CCRT Syed Kazmi, MD

Opponent favoring CTH

Mohamed Algarni, MD

Moderator Mussadique Ali, MD

Proponent favoring direct metastatic therapy

Mohamed Alghamdi, MD

Opponent against direct metastatic therapy Waleed Ghareeb, MD

Moderator Waad Awad, MD

Proponent favoring laparoscopic staging Zyad Alyahya, MD

Opponent against laparoscopic staging Hassan Alrobaidi, MD

Moderator Badr Alshamsan, MD

Proponent favoring IO Ahmed Shehri, MD

Opponent favoring FLOT Ahmad Alzahrani, MD

Moderator Khalid Alkhatib, MD

Proponent favoring PDL Emad Taskhandi, MD

Opponent favoring all comers Turkie Alfayea, MD

Moderator Ahmad Badeeb, MD

Speaker Walid Selwi, MD

Moderator

Fahad Ibn Shamsah, MD

DAY 2: SATURDAY, 09 March 2024

SESSION 6: HEPATOBILIARY

11:40AM - 11:50 AM ICI in adjuvant HCC

11:50AM - 12:00 PM Yes vs. No

12:00 PM - 12:10 PM Discussion

12:10PM - 12:30 PM Lunch break/Prayer time

12:30 PM - 12:40 PM Systemic vs systemic + additional local therapy in metastatic HCC

12:40 PM - 12:50 PM

12:50 PM - 1:00 PM Discussion

1:00 PM - 1:10 PM IO/IO vs IO/anti VEGF in mHCC first line

1:10 PM - 1:20 PM IO/IO vs IO/anti VEGF

1:20 PM - 1:30 PM Discussion

1:30 PM - 1:40 PM Adjuvant chemo-radiation in margin +, node+ cholangiocarcinoma

1:40 PM - 1:50 PM Yes vs. No

1:50 PM - 2:00 PM Discussion

2:00 PM - 2:10 PM Optimal first line treatment of advanced pancreatic cancer

2:10 PM - 2:20 PM Folfirinox vs Nalirinox

2:20 PM - 2:30 PM Discussion

2:30 PM - 2:40 PM Neoadjuvant CRT vs neoadjuvant CTH in borderline pancreatic cancer

2:40 PM - 2:50 PM Neoadjuvant CCRT vs neoadjuvant CTH

2:50 PM - 3:00 PM Discussion

Proponent favoring IO use Fahad Ibn Shamsah, MD

Opponent against IO use Abdulrahman Albaradie, MD

Moderator Adil Nazir, MD

Proponent favoring additional local therapy Abdelhameed Alfagih,MD

Opponent against Ashwaq Alolayan, MD

Moderator Amal Aljuhani, MD

Proponent favoring IO/IO Abdulraheem Shangiti, MD

Opponent favoring IO/VEGF Ali Alqahtani, MD

Moderator Abdullah Alruwaili, MD

Proponent favoring CCRT Khalid Alrabiah, MD

Opponent against CCRT Ahmed Allehebi, MD

Moderator Mustafa Almubarak, MD

Proponent favoring Folfirinox Mahmoud Shenawy, MD

Opponent Favoring Nalirinox Samah Alrehaili, MD

Moderator Nermin Arroug, MD

Proponent favoring CCRT Hossam Alasaf, MD

Opponent favoring CTH Ali Aljubran, MD

Moderator

Yazeed Alomar, MD

DAY 2: SATURDAY, 09 March 2024

3:00PM - 3:10 PM Break time

SATELLITE SYMPOSIUM | Sponsored by : Merck Sharp & Dohme (MSD)

3:10 PM - 3:40 PM Evolution of Immunotherapy in the Management of 1LmCRC (MSI-H/d-MMR) Speaker Kanan Alshammari, MD

Moderator

SESSION 7: COLON CANCER

3:40 PM - 3:50 PM Viability of Pelvic Exenteration for Locally Advanced Rectal Cancer: Is it the Way to go? Proponent for Yes Raha Alahmadi, MD

3:50 PM - 4:00 PM Yes vs. No Opponent for No Khaled Madbouly, MD

4:00 PM - 4:10 PM Discussion Moderator Reem Alsuwailem, MD

4:10 PM - 4:20 PM ctDNA as guidance of treatment of stage 2 colon cancer Proponent favoring ctDNA Shouki Bazarbashi, MD

4:20 PM - 4:30 PM Yes vs. No Opponent against ctDNA Ali Alfakeeh, MD

4:30 PM - 4:40 PM Discussion Moderator Bashayer Alenizi, MD

4:40 PM - 4:50 PM Adjuvant CTH post resection of metachronaus advanced CRC Proponent favoring CTH Mervat Mahrous, MD

4:50 PM - 5:00 PM Yes vs. No Opponent against CTH Shereef Elsamany, MD

5:00 PM - 5:10 PM Discussion

Moderator Shadi Alkhayyat, MD

5:10 PM - 5:20 PM Re-challenge CTH vs standard 3rd line treatment in advanced CRC Proponent favoring re-challenge CTH Ahmad Refae, MD

5:20 PM - 5:30 PM Re-challenge CTH vs 3rd line treatment

5:30 PM - 5:40 PM Discussion

5:40 PM - 5:50 PM Omitting radiation therapy in early rectal cancer

5:50 PM - 6:00 PM Yes vs. No

6:00 PM - 6:10 PM Discussion

Opponent favoring 3rd line Ayman Omar, MD

Moderator Yasamyian Alsgaih, MD

Proponent favoring Yes Maymoona Altarturi, MD

Opponent favoring No Abdullah Alsuhaibani, MD

Moderator Ali Alhanash, MD

6:10 PM - 6:20 PM Neoadjuvant Treatment of MSI-H Locally Advanced Rectal Cancer Proponent favoring IO Kanan Alshammari, MD

6:20 PM - 6:30 PM IO vs Standard treatment Opponent favoring standard treatment Ibrahim Madkhali, MD

6:30 PM - 6:40 PM Discussion Moderator Waleed Selwi, MD

6:40PM - 6:50 PM Closing

3rd

Satellite Symposium

08 March 2024 – Virtual 2:30 PM – 3:00 PM

Recent Advances in 1st Line mRCC

Speaker

Dr. Jens Bedke

3rd

Satellite Symposium

08 March 2024 – Virtual 4:40 PM – 5:10 PM

Sequencing in Management of mUC

Speaker:

Faisal Azam, MD

Consultant, Adult Oncology Department

King Fahad Specialist Hospital- Dammam

3rd

Satellite Symposium

09 March 2024 – Virtual 11:10 – 11:40 AM

Role of IO in Treating UGI Cancers

Speaker

Walid Selwi, MD

3rd

Satellite Symposium

09 March 2024 – Virtual 3:10 PM – 3:40 PM

Evolution of Immunotherapy in the Management of 1LmCRC (MSI-H/d-MMR)

Speaker:

Kanan Alshammari, MD

Medical Oncology Consultant

Department of Medical Oncology

King Abdulaziz Medical City – Central Region

SultanAlkhateeb, MD

Consultant, Urology and Urological

Deputy Chairman Department ofUrology

King FaisalSpecialistHospitaland Research Centre

Chairman, ScientificCouncil ofthe Saudi Boardof Urology , SaudiCommission forHealth Specialties– Riyadh

BassamBasulaiman, MD

Consultant, MedicalOncology Department

Comprehensive CancerCenter

King FahadMedicalCity – Riyadh

Role of radical nephrectomy in mRCC Surgery vs Non-Surgery

Abdulrahman Alloghbi, MD

Head of E-learning Unit College of Medicine, King Khalid University

Mohamed Aseafan MD

Consultant, Adult Medical Oncology Security Forces Hospital - Riyadh

Role of immunotherapy in metastatic non clear RCC

Yes vs Against

Safwan Bahkhsh, MD

Consultant Medical Oncology King Faisal Specialist Hospital & Research Center- Jeddah

Role of adjuvant immunotherapy in invasive urothelial cancer Adjuvant Immunotherapy vs No

Marwan Al-Hajeili MD Consultant, Oncology Fakeeh Hospital, Jeddah

Head of Clinical Trials Unit

Associate Professor, Oncology

King Abdulaziz University Jeddah

Roula Mufti, MD

Consultant/ Medical Oncologist

King Abdulaziz Medical City Jeddah, Makkah Region

Assistant professor, KSAUH

Triplet therapy vs doublet therapy in hormone sensitive prostate cancer

Triplet Therapy vs Doublet Therapy

Abdullah Alsharm MD

Medical Director/ Consultant

Comprehensive Cancer Centre

King Fahd Medical City - Riyadh

PROPONENTS OPPONENTS

Amin Eltigani, MD

Consultant Medical Oncology

Prince Mohammed Bin Abdulaziz Hospital Ministry of National Guard – Health Affairs Al Madinah

Hormone followed by hormone treatment vs hormone followed by chemo/others HR>HR vs HR>Chemo

Nedal Bukhari, MD

Consultant, Medical Oncologist

Prince Sultan Military Medical City, Saudi Arabia

Faisal Azam, MD

Consultant, Adult Oncology Department

King Fahad Specialist Hospital- Dammam

PET

PSMA guided in oligometastatic castrate sensitive prostate cancer

Yes or No

Muhammad Rauf, MD

Consultant, Medical Oncology

King Faisal Specialist Hospital and Research Centre- Riyadh

Testicular cancer beyond first line

High dose chemotherapy vs conventional chemo

Faisal Albadainah MD

Consultant, Medical Oncology Oncology Center

King Abdullah Medical City (KAMC)

Makkah, Saudi Arabia

Sharif Kullab MD

Consultant Medical Oncology

Director, Medical Oncology Fellowship Program

King Saud University Medical City

Syed Kazmi, MD

Consultant, General Radiation Oncology

Department of Radiation Oncology

King Faisal Specialist Hospital and Research Centre –Riyadh

Treatment of localized GEJ tumors: Neo-adjuvant treatment CCRT vs CTH

Mohamed Algharni, MD

Section Head, Cancer Control & Outreach Division

Consultant, Medical Oncologist and Clinical Cancer Genetics

Consultant

Ministry of National Guard Health Affairs

Assistant Professor, King Saud Bin Abdulaziz University for Health Science

Mohammed Alghamdi, MD

Consultant, Adult Medical Oncologist

Deputy Director & Head of Medical Oncology Unit, Oncology Centre

King Saud University Medical City-Riyadh

Treatment of oligometastatic GEJ adenocarcinoma metastatic directed therapy

Yes vs. No

Waleed Alghareeb MD

Consultant Medical Oncologist

Dr. Sulaiman Al-Habib Hospita in Alsweidi, Riyadh, Saudi Arabia

Zyad Alyahya, MD

Associate Consultant, General & Upper Gi Surgery

Department of Surgery

King Faisal Specialist Hospital and Research Centre – Riyadh

Ahmed Alshehri MD

Assistant Professor, Internal Medicine Oncology

King Saud University for Health Sciences – Jeddah-Makkah

Role of staging laparoscopy in gastric cancer

Yes vs. No

Neoadjuvant treatment for MSI-H gastric GEJ tumor CTH vs. ICI

Hassan Alrobaidi MD

Consultant, Thoracic Surgery

Lung Health Centre Department

King Faisal Specialist Hospital and Research Centre – Riyadh

Ahmad Alzahrani, MD

Director, Medical Oncology

Fellowship Training Program

Director, Clerkship Alfaisal University Oncology/Hematology

Consultant, GI/GU Oncology

Dept. of Medical Oncology, Oncology Centre

King Faisal Specialist Hospital and Research Centre – Riyadh

Emad Tashkandi, MD

Consultant Medical Oncologist, King Abdullah Medical City

Assistant Professor, Dept. of Medicine, Umm AlQura University

Makkah, Saudi Arabia

Role of ICI in metastatic gastric cancer: All or PDL expressors only

Turki Alfayea, MD

Consultant, Internal Med & Adult Med Onc

King Abdullah Specialized Children’s Hospi

King Abdulaziz Medical City/Ministry of National Guard

Assistant Professor/Medicine & Oncology King Saud Bin Abdulaziz University for Health Science (KSAU-HS) – Riyadh

FahadIbnShamsah, MD

Chairman/ Consultant

Adult MedicalOncology

Oncology Centre KFSH- Dammam

Director,OutreachProgram

King Fahad SpecialistHospital-Dammam

ICI in adjuvant HCC

Yes vs. No

Abdulrahman Albaradie MD

Consultant, Medical Onology

Al -Hada Armed Forces Hospital, Saudi Arabia

Abdelhameed Alfagih, MD

Medical Oncology Consultant

Chairperson, Cancer Center Research group

Comprehensive Cancer Center, King Fahad Medical City, KFMC - Riyadh, Saudi Arabia

Systemic vs systemic + additional local therapy in metastatic HCC

Ashwaq Alolayan, MD

Deputy Chairman, Oncology Quality & Patient Safety

Section Head, Div. of Adult Medical Oncology

King Abdullah Specialized Children’s Hospital

Ministry of National Guard-Health Affairs-Riyadh

Abdulraheem Alshangiti, MD

Chairman, Medical Oncology Department

Consultant, Internal Medicine and Medical Oncology

King Fahad Specialist Hospital Dammam

Ali Alqahtani, MD

Hematology/Oncologist Georgetown Lombardi

Comprehensive Cancer Center Washington, DC, USA

Khalid Alrabiah, MD

Associate Consultant, General Radiation Oncology

Radiation Oncology Department

Cancer Centre of Excellence

King Faisal Specialist Hospital and Research Centre- Riyadh

Adjuvant chemo-radiation in margin+, node+ cholangiocarcinoma

Yes vs. No

Ahmad Allehebi, MD

Medical Oncologist

GI and Lung Malignancies

King Faisal Specialist Hospital and Research Centre –Jeddah, Saudi Arabia

Mahmoud Elshenawy, MD

Associate Professor, Clinical Oncology

Faculty of Medicine, Menoufia University, Egypt

Assistant Consultant, General Oncology

Medical Oncology Department, Cancer Centre of Excellence

King Faisal Specialist Hospital and Research Centre- Riyadh

Optimal first line treatment of advanced pancreatic cancer

Folfirinox vs Nalirinox

Samah Alrehaili, MD Specialist Consultant, Adult Medical Oncology/Lung and GI

National Guard Health Affairs – Jeddah

Hossam Alasaf, MD

Chief Executive Officer, BaraSeen Medical BaTiK X for Radiotherapy Services

Radiation Oncologist

King Fahad Medical City

Comprehensive Cancer Center

Riyadh, Saudi Arabia

Raha Alahmadi, MD

Consultant Colorectal Surgery

Department of Surgery

King Faisal Specialist Hospital and Research Centre - Riyadh

Neoadjuvant CRT vs neoadjuvant CTH in borderline metastatic pancreatic cancer

Neoadjuvant CCRT vs neoadjuvant CTH

Ali Aljubran MD

Section Head & Consultant, GI/GU Oncology Medical Oncology Department

Chairman, Oncology Clinical Research Committee

Adjunct Professor, College of Medicine, Al Faisal University

King Faisal Specialist Hospital and Research Centre – Riyadh

Viability of Pelvic Exenteration for Locally Advanced Rectal Cancer –Is It The Way to Go?

Yes or No

Khaled Madbouly, MD

Professor & Chairman of Colorectal Surgery, Alexandria University

Consultant Colorectal Surgeon, Burjeel Royal Hospital, UAE

PROPONENTS

Shouki Bazarbashi, MD

Acting Director, Oncology Center Consultant, Section of Medical Oncology

King Faisal Specialist Hospital & Research Center

Adjunct professor, College of Medicine, Alfaisal University Riyadh

ctDNA as guidance of treatment of stage 2 colon cancer

Yes vs. No

Ali Alfakeeh, MD Chairman, Consultant, Medical Oncologist

Adult Medical Oncology

Department Comprehensive Cancer Center King Fahad Medical City – Riyadh

OPPONENTS

Mervat Mahrous, MD

Oncology consultant

Associate Professor of Oncology

Prince Sultan Military Medical City Riyadh

Adjuvant CTH post resection of metachronaus advanced CRC

Yes or No

Shereef Elsamany, MD Head, Medical Oncology

King Abdullah Medical City, Makkah, Saudi Arabia

Professor of Medical Oncology, Oncology Center, Mansoura University, Egypt

Ahmad Abdulfatah Refae, MD Consultant, Adult Oncology

International Medical Center

Jeddah, KSA

Associate Professor

Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain- Shams University, Cairo, Egypt

Re-challenge CTH vs standard 3rd line treatment in advanced CRC

Re-challenge CTH vs 3rd Line Treatment

Ayman Omar, MD

Assistant Consultant, Breast Cancer, Medical Oncology Department

Cancer Centre of Excellence

King Faisal Specialist Hospital & Research Centre-Riyadh

PROPONENTS OPPONENTS

Maymoona Altarturi, MD Assistant Consultant, Medical Oncology Department

Cancer Centre of Excellence

King Faisal Specialist Hospital and Research Centre- Riyadh

Omitting radiation therapy in early rectal cancer

Yes or No

Abdullah Alsuhaibani, MD Head, Radiation Oncology Program Director, Radiation Oncology Residency Program Oncology Center

King Saud University Medical City

Kanan Alshammari, MD

Medical Oncology Consultant

Department of Medical Oncology

King Abdulaziz Medical City –Central Region

Neoadjuvant treatment of MSI-H locally advanced rectal cancer –IO vs standard treatment

Ibrahim Madkhali MD

Medical Oncology Consultant

Chief of Oncology Department

Prince Mohammed Bin Nasser Hospital - Jazan

ORGANIZING COMMITTEE

Conference Chairman:

Shouki Bazarbashi, MD

Head, Organizing Committee:

Ahmed Badran Sobh, MD

Members:

Ali Aljubran, MD

Ahmad Alzahrani, MD

Muhammad Rauf, MD

Fahad Almugbel, MD

Ali Alqahtani, MD

Mahmoud Elshenawy, MD

Dr Ayman Omar, MD

Maymoona Altarturi, MD

Eduardo Dumrique

SPONSORS